Gene

NFKBIZ

NFKB inhibitor zeta

Explore in graph →CI-GENE-00016698HGNC:29805 ENSG00000144802 NCBI 64332 CIViC Approved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
NFKBIZ 3-prime UTR mutation1
(oncogenic)	Diffuse Large B-Cell LymphomaCURATED_BROADER	Oncogenic	E	Supports Oncogenicity	4	submitted	EID11968 The authors performed an integrative analysis of genomes, exomes and transcriptome data from DLBCL and identified recurrent coding and non-coding loci that are commonly mutated in DLBCL PMID 30275490 · Arthur et al., 2018 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (4)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved4 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Comparison of Cutaneous Sarcomas, CSCC and Deeper Sarcomas (DFCI, 2026) sarcoma_dfci_genie_2026	unmapped	Ssm	3	48	6.3%	187

Literature

Linked publications (0)

Data not yet available

No publication linked to this gene yet.